What is the success rate of stem cell therapy for Long COVID?
No valid universal success rate exists for cell therapy in long COVID. Definitions, natural course and symptoms vary; review randomised comparator, prespecified phenotype, validated function and quality-of-life outcomes, post-exertional effects, adverse events and complete follow-up.
What the evidence shows for Long COVID
Cell-product evidence remains investigational and must specify case definition, prior illness, phenotype, exact product, route, comparator, validated symptom and function outcomes, safety and follow-up. The FDA regenerative-medicine patient page states that these therapies have not been approved in the United States for treatment or prevention of COVID-19 or its complications. A registry entry or biomarker change is not efficacy.
Am I a candidate? → · Long COVID: full overview → · Long COVID cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.